Home/Pipeline/THEO-741

THEO-741

Colorectal Cancer

Pre-clinicalActive

Key Facts

Indication

Colorectal Cancer

Phase

Pre-clinical

Status

Active

Company

Theolytics

About Theolytics

Theolytics is a clinical-stage biotech founded in 2017 in Oxford, UK, focused on developing next-generation oncolytic virus therapies for solid tumors. Its core innovation is the ADENOVO platform, which uses Darwinian selection on actual patient tumors to identify viruses optimized for efficacy, delivery, and manufacturing. With a lead candidate in Phase 1/2 trials for ovarian cancer and a pipeline targeting other indications, the company aims to overcome the significant barriers posed by the tumor stroma and microenvironment.

View full company profile

Therapeutic Areas

Oncology

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
M9140	Merck KGaA	Phase 1/2	Active
Repositioned/Rerouted API	Reponex	Not Specified	Active
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
Cannabics® RCC-33	CNBX Pharmaceuticals	Preclinical	Preparation of Pre-IND Meeting Package
VCR-036	Vicero Bio	Preclinical	Active
CBI-1214	Cartography Biosciences	Phase 1	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active